Scholar Rock Ownership | Who Owns Scholar Rock?
Scholar Rock Ownership Summary
Scholar Rock is owned by 88.98% institutional investors, 1.07% insiders, and 9.95% retail investors. Artal group is the largest institutional shareholder, holding 11.74% of SRRK shares. T. Rowe Price New Horizons is the top mutual fund, with 4.90% of its assets in Scholar Rock shares.
SRRK Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Scholar Rock | 88.98% | 1.07% | 9.95% |
| Sector | Healthcare Stocks | 49.73% | 8.84% | 41.43% |
| Industry | Biotech Stocks | 47.04% | 8.74% | 44.21% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Artal group | 11.26M | 11.74% | $93.79M |
| Fmr | 9.89M | 10.31% | $82.36M |
| Price t rowe associates inc /md/ | 8.19M | 8.54% | $68.21M |
| Samsara biocapital | 6.79M | 7.08% | $56.55M |
| Blackrock | 5.66M | 5.91% | $47.18M |
| Redmile group | 5.45M | 5.69% | $45.42M |
| Vanguard group | 3.84M | 4.00% | $31.96M |
| Eventide asset management | 3.07M | 3.21% | $25.61M |
| Polar capital | 2.94M | 3.07% | $24.50M |
| State street | 2.81M | 2.93% | $23.40M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Samsara biocapital | 6.79M | 11.84% | $56.55M |
| Redmile group | 5.45M | 2.75% | $45.42M |
| Artal group | 11.26M | 2.39% | $93.79M |
| Eventide asset management | 3.07M | 0.44% | $25.61M |
| Integral health asset management | 400.00K | 0.32% | $3.33M |
| Bellevue group | 2.17M | 0.29% | $18.04M |
| Orbimed advisors | 1.07M | 0.18% | $8.95M |
| Polar capital | 2.94M | 0.14% | $24.50M |
| Hood river capital management | 832.79K | 0.14% | $6.94M |
| Values first advisors | 25.98K | 0.13% | $216.41K |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Eventide asset management | 3.07M | 0.44% | 1.56M |
| Vanguard group | 3.84M | 0.00% | 867.03K |
| Clearbridge investments | 747.11K | 0.01% | 747.11K |
| Candriam s.c.a. | 744.44K | 0.04% | 744.44K |
| Blackrock | 5.66M | 0.00% | 658.53K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Orbimed advisors | 1.07M | 0.18% | -2.50M |
| State street | 2.81M | 0.00% | -1.36M |
| Bioimpact capital | - | - | -1.03M |
| Redmile group | 5.45M | 2.75% | -966.53K |
| Fmr | 9.89M | 0.01% | -715.14K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Clearbridge investments | 747.11K | 0.01% | 747.11K | $6.22M |
| Candriam s.c.a. | 744.44K | 0.04% | 744.44K | $6.20M |
| Renaissance | 92.36K | 0.00% | 92.36K | $769.39K |
| E. ohman j:or asset management ab | 92.00K | 0.02% | 92.00K | $766.36K |
| Exchange traded concepts | 58.22K | 0.01% | 58.22K | $484.99K |
Sold Out
| Holder | Change |
|---|---|
| Nelson, van denburg & campbell wealth management group | -11.00 |
| Ifp advisors | -30.00 |
| Innealta capital | -48.00 |
| National bank of canada /fi/ | -104.00 |
| Pacer advisors | -756.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2024 | 172 | 3.61% | 86,355,530 | 1.71% | 88 | 1.13% | 84 | -16.83% | 53 | 26.19% |
| Jun 30, 2024 | 166 | 1.22% | 84,906,035 | 0.71% | 88 | 1.15% | 101 | 12.22% | 42 | -8.70% |
| Mar 31, 2024 | 164 | 22.39% | 84,308,074 | 4.71% | 87 | 0.94% | 90 | -21.05% | 46 | 318.18% |
| Dec 31, 2023 | 134 | 47.25% | 80,517,894 | 49.48% | 96 | 2.16% | 114 | 70.15% | 11 | -26.67% |
| Sep 30, 2023 | 91 | 5.81% | 53,866,941 | 5.18% | 66 | 1.64% | 67 | 8.06% | 15 | -6.25% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| T. Rowe Price New Horizons | 3.92M | 4.90% | -12.35K |
| US Small-Cap Growth II Equity Comp | 3.92M | 4.90% | -13.94K |
| Fidelity Growth Compy Commingled Pl O | 3.59M | 4.49% | 36.80K |
| Fidelity Growth Compy Commingled Pl S | 3.66M | 4.05% | 66.86K |
| Polar Capital Biotech S Inc | 2.75M | 3.05% | - |
| Fidelity Growth Company Fund | 2.75M | 3.04% | 28.23K |
| BB Biotech AG Ord | 2.13M | 2.66% | - |
| Vanguard Total Stock Mkt Idx Inv | 2.42M | 2.63% | 125.53K |
| T. Rowe Price Health Sciences | 1.72M | 2.15% | 140.59K |
| Eventide Healthcare & Life Sciences I | 1.69M | 2.11% | 622.61K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Dec 10, 2024 | Invus Public Equities, L.P. | - | Sell | $66.64M |
| Nov 25, 2024 | Invus Public Equities, L.P. | - | Sell | $1.23M |
| Nov 25, 2024 | Invus Public Equities, L.P. | - | Sell | $7.84M |
| Nov 25, 2024 | Invus Public Equities, L.P. | - | Sell | $1.69M |
| Nov 25, 2024 | Invus Public Equities, L.P. | - | Sell | $5.00M |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2024 Q4 | - | 25 |
| 2024 Q3 | - | 2 |
| 2024 Q2 | - | 4 |
| 2024 Q1 | - | 9 |
| 2023 Q4 | 4 | 5 |
SRRK Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools